 BEIJING, May 23, 2022 GLOBE NEWSWIRE -- Genetron Holdings Limited Genetron Health or the Company, NASDAQ: GTH, a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. 